Trastuzumab by inducing overexpression of B7-H4 on TAMs contributes to the poor prognosis, but the concomitant treatment of trastuzumab with the use of the anti-B7-H4 neutralizing antibody markedly increased ADCP of HER2+ BC cells and strengthened the response against these cells in vitro and in vivo [164]. Here, ERBB2 is linked to breast cancer.